A carregar...
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
A major complication in treating hemophilia A is the development of neutralizing antibodies (inhibitors) against therapeutic administered factor VIII (FVIII), which occurs in approximately 20-30% of patients with severe disease. These inhibitors render FVIII replacement therapy ineffective and incre...
Na minha lista:
| Publicado no: | Int J Mol Cell Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Babol University of Medical Sciences
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7422849/ https://ncbi.nlm.nih.gov/pubmed/32832483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.22088/IJMCM.BUMS.9.1.33 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|